Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory pharmacogenomic study of cetuximab monotherapy in metastatic EGFR-positive colorectal carcinoma
2004-002837-37Phase 2Completed
- Sponsor
- Merck Santé
- Start
- May 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Merck Santé. Primary endpoint: Tumor response. Started May 2005; status: completed.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2004-002837-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002837-37.